357 related articles for article (PubMed ID: 28487615)
1. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease.
Dong S; Zhan ZY; Cao HY; Wu C; Bian YQ; Li JY; Cheng GH; Liu P; Sun MY
World J Gastroenterol; 2017 Apr; 23(15):2771-2784. PubMed ID: 28487615
[TBL] [Abstract][Full Text] [Related]
2. Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis.
Qi S; Xu D; Li Q; Xie N; Xia J; Huo Q; Li P; Chen Q; Huang S
Clin Chim Acta; 2017 Oct; 473():89-95. PubMed ID: 28842175
[TBL] [Abstract][Full Text] [Related]
3. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.
Masarone M; Troisi J; Aglitti A; Torre P; Colucci A; Dallio M; Federico A; Balsano C; Persico M
Metabolomics; 2021 Jan; 17(2):12. PubMed ID: 33458794
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive distinction of non-alcoholic fatty liver disease using urinary volatile organic compound analysis: early results.
Arasaradnam RP; McFarlane M; Daulton E; Westenbrink E; O'Connell N; Wurie S; Nwokolo CU; Bardhan KD; Savage RS; Covington JA
J Gastrointestin Liver Dis; 2015 Jun; 24(2):197-201. PubMed ID: 26114180
[TBL] [Abstract][Full Text] [Related]
5. Plasma metabolomic profile in nonalcoholic fatty liver disease.
Kalhan SC; Guo L; Edmison J; Dasarathy S; McCullough AJ; Hanson RW; Milburn M
Metabolism; 2011 Mar; 60(3):404-13. PubMed ID: 20423748
[TBL] [Abstract][Full Text] [Related]
6. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.
Alonso C; Fernández-Ramos D; Varela-Rey M; Martínez-Arranz I; Navasa N; Van Liempd SM; Lavín Trueba JL; Mayo R; Ilisso CP; de Juan VG; Iruarrizaga-Lejarreta M; delaCruz-Villar L; Mincholé I; Robinson A; Crespo J; Martín-Duce A; Romero-Gómez M; Sann H; Platon J; Van Eyk J; Aspichueta P; Noureddin M; Falcón-Pérez JM; Anguita J; Aransay AM; Martínez-Chantar ML; Lu SC; Mato JM
Gastroenterology; 2017 May; 152(6):1449-1461.e7. PubMed ID: 28132890
[TBL] [Abstract][Full Text] [Related]
7. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
[TBL] [Abstract][Full Text] [Related]
8. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
9. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
[TBL] [Abstract][Full Text] [Related]
10. Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.
Ferslew BC; Xie G; Johnston CK; Su M; Stewart PW; Jia W; Brouwer KL; Barritt AS
Dig Dis Sci; 2015 Nov; 60(11):3318-28. PubMed ID: 26138654
[TBL] [Abstract][Full Text] [Related]
11. A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease.
Ganesan R; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Kim DJ; Suk KT
Life Sci; 2023 Jun; 322():121626. PubMed ID: 37003543
[TBL] [Abstract][Full Text] [Related]
12. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.
Sa R; Zhang W; Ge J; Wei X; Zhou Y; Landzberg DR; Wang Z; Han X; Chen L; Yin H
J Mol Cell Biol; 2016 Jun; 8(3):195-206. PubMed ID: 26993042
[TBL] [Abstract][Full Text] [Related]
13. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
[TBL] [Abstract][Full Text] [Related]
14. Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B.
Yang RX; Hu CX; Sun WL; Pan Q; Shen F; Yang Z; Su Q; Xu GW; Fan JG
Sci Rep; 2017 Sep; 7(1):10517. PubMed ID: 28874844
[TBL] [Abstract][Full Text] [Related]
15. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.
Loomba R; Quehenberger O; Armando A; Dennis EA
J Lipid Res; 2015 Jan; 56(1):185-92. PubMed ID: 25404585
[TBL] [Abstract][Full Text] [Related]
16. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis.
Zhu Q; Li H; Ao Z; Xu H; Luo J; Kaurich C; Yang R; Zhu PW; Chen SD; Wang XD; Tang LJ; Li G; Huang OY; Zheng MH; Li HP; Liu F
J Nanobiotechnology; 2022 Jul; 20(1):349. PubMed ID: 35897102
[TBL] [Abstract][Full Text] [Related]
17. Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors.
Tiwari-Heckler S; Gan-Schreier H; Stremmel W; Chamulitrat W; Pathil A
Nutrients; 2018 May; 10(5):. PubMed ID: 29883377
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
[TBL] [Abstract][Full Text] [Related]
19. Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment.
Miccheli A; Capuani G; Marini F; Tomassini A; Praticò G; Ceccarelli S; Gnani D; Baviera G; Alisi A; Putignani L; Nobili V
Int J Obes (Lond); 2015 Jul; 39(7):1118-25. PubMed ID: 25809828
[TBL] [Abstract][Full Text] [Related]
20. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
